Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | PPARD | Q03181 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.48 |
| ▸ | ICMT | O60725 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8181593 | 0.92 | LMNA (0.65) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL8166827 | 0.91 | LMNA (0.70) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL8178901 | 0.89 | ALDH1A1 (0.60) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL8178903 | 0.88 | ALDH1A1 (0.67) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL8183005 | 0.86 | ALDH1A1 (0.62) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL8167182 | 0.85 | LMNA (0.74) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL13931422 | 0.85 | LMNA (0.67) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL13931026 | 0.85 | ALDH1A1 (0.65) | LMNAALDH1A1PPARDPPARGPPARA | |
| SCHEMBL13952534 | 0.84 | ALDH1A1 (0.44) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8179889 | 0.84 | LMNA (0.60) | LMNAALDH1A1PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | LMNA 2969/4885ALDH1A1 1836/4885PPARD 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.